Interstitial Lung Disease

Interstitial Lung Disease — scientific infographic poster

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology — Fibrosis Mechanisms
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis — Pulmonary Function Tests, High-Resolution CT, Bronchoscopy, Surgical Biopsy
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. Overview

Interstitial lung disease (ILD) is an umbrella term encompassing over 200 distinct disorders characterized by diffuse inflammation and/or fibrosis of the pulmonary interstitium — the tissue and space surrounding alveoli, capillaries, and bronchioles. Though structurally the interstitium is the primary target, ILDs invariably affect alveolar epithelium, capillary endothelium, and airspaces as well. The result is progressive impairment of gas exchange and lung mechanics, leading to restrictive physiology, hypoxemia, and functional decline.

The most clinically significant ILD is idiopathic pulmonary fibrosis (IPF), the prototype of the progressive fibrosing ILDs. Other major categories include connective tissue disease-associated ILD (CTD-ILD), hypersensitivity pneumonitis (HP), sarcoidosis, occupational/environmental ILDs, and drug-induced ILD. Accurate classification is critical because prognosis and treatment vary substantially among subtypes.

2. Epidemiology

The prevalence of all ILDs combined is estimated at 80–100 per 100,000 in the United States. IPF, the most common idiopathic IIP, has an estimated prevalence of 14–43 per 100,000 and incidence of 7–16 per 100,000 per year. IPF is predominantly a disease of older males (>60 years), with a strong association with cigarette smoking.

CTD-ILD is the most common ILD category overall; systemic sclerosis (SSc) is complicated by ILD in 70–90% of patients (though progressive disease in ~15%), and rheumatoid arthritis ILD affects approximately 10–20% of rheumatoid arthritis (RA) patients. Hypersensitivity pneumonitis accounts for up to 15% of ILD diagnoses in tertiary centers. Occupational ILDs (silicosis, asbestosis, coal worker's pneumoconiosis) remain significant public health concerns globally.

Drug-induced ILD is increasingly recognized with >350 implicated medications (bleomycin, amiodarone, methotrexate, nitrofurantoin, immune checkpoint inhibitors). ILD incidence is increasing, partly reflecting improved recognition and an aging population.

3. Pathophysiology — Fibrosis Mechanisms

The mechanisms underlying ILD vary by subtype, but converge on two principal processes: alveolar inflammation and/or aberrant fibrogenesis.

Inflammatory ILDs (e.g., Hypersensitivity Pneumonitis, CTD-ILD)

Repetitive exposure to antigenic or injurious stimuli triggers innate and adaptive immune responses. Alveolar macrophages, T lymphocytes (particularly Th1/Th17 in HP), and neutrophils accumulate in the interstitium. Macrophage-derived cytokines (interleukin-1 (IL-1), tumor necrosis factor-alpha, interleukin-6 (IL-6)) amplify inflammation. In some cases, inflammation resolves; in others, it progresses to fibrosis via TGF-beta-mediated activation of fibroblasts and myofibroblasts.

Fibrotic ILDs — IPF Paradigm

IPF is driven by aberrant alveolar epithelial repair rather than primary inflammation. Repetitive micro-injuries (cigarette smoke, viral infections, gastroesophageal reflux microaspiration, mechanical stress in susceptible individuals) trigger abnormal type II alveolar epithelial cell (AEC II) responses: apoptosis, senescence, and epithelial-mesenchymal transition (EMT). Key molecular mechanisms:

Histologically, IPF demonstrates the usual interstitial pneumonia (UIP) pattern: temporally heterogeneous fibrosis (alternating areas of fibrosis and near-normal lung), fibroblastic foci (leading edges of active fibrosis), honeycomb changes (cystic airspace remodeling) predominantly in the subpleural, basal lung.

4. Etiology and Risk Factors

ILDs are classified by etiology:

Idiopathic Interstitial Pneumonias (IIPs)

Connective Tissue Disease-Associated ILD

Hypersensitivity Pneumonitis

Occupational and Environmental ILDs

Drug-Induced ILD

Risk Factors for ILD in General

5. Clinical Presentation

ILD typically presents with an insidious onset of symptoms, often leading to significant delay in diagnosis (median 1–2 years for IPF).

Symptoms:

Physical examination findings:

6. Diagnosis — Pulmonary Function Tests, High-Resolution CT, Bronchoscopy, Surgical Biopsy

Pulmonary Function Tests (PFTs)

The hallmark of ILD is a restrictive ventilatory defect:

FVC decline of ≥10% or DLCO decline ≥15% over 6–12 months predicts disease progression and mortality in IPF.

High-Resolution CT (HRCT)

The cornerstone of ILD diagnosis. Computed tomography (CT) patterns guide diagnosis and can obviate surgical biopsy:

Bronchoscopy with Bronchoalveolar Lavage (BAL)

BAL cellular analysis provides diagnostic clues:

Surgical Lung Biopsy (SLB)

Video-assisted thoracoscopic surgery (VATS) biopsy provides the largest tissue samples and remains the gold standard for histopathologic diagnosis when HRCT is non-diagnostic. Samples are usually taken from multiple lobes. Operative mortality and morbidity risk are weighed against diagnostic benefit; surgical biopsy may be deferred in elderly, physiologically compromised patients or where the clinical and CT picture is sufficiently diagnostic.

Serological Testing

Multidisciplinary Discussion (MDD)

Integration of clinical, radiological, and pathological data in a dedicated ILD multidisciplinary team (pulmonologist, thoracic radiologist, pathologist) is the recommended diagnostic approach and demonstrably improves diagnostic accuracy and inter-observer agreement.

7. Treatment

Treatment is highly ILD-subtype-specific. Inflammatory ILDs may respond to immunosuppression; fibrotic ILDs (particularly IPF) do not benefit and may worsen with corticosteroids.

Idiopathic Pulmonary Fibrosis

CTD-ILD

Progressive Pulmonary Fibrosis

The 2022 ATS/ERS/JRS/ALAT guideline defines progressive pulmonary fibrosis in a person with an ILD other than IPF as at least two of three findings within the past year, with no other explanation: worsening symptoms, progression on imaging, and progression on lung function tests. It conditionally recommends nintedanib and asks for more research on pirfenidone.

Hypersensitivity Pneumonitis

Organizing Pneumonia

8. Complications

9. Prognosis

Prognosis is highly subtype-dependent:

The GAP (Gender, Age, Physiology) Index and staging system (incorporating FVC and DLCO) has been validated to predict 1-, 2-, and 3-year mortality in IPF and other fibrotic ILDs.

10. Prevention

11. Recent Research and Advances

INBUILD Trial: Demonstrated that nintedanib reduces FVC decline in progressive fibrosing ILDs other than IPF (including NSIP, HP, RA-ILD, SSc-ILD), establishing the concept of a common progressive fibrosis phenotype amenable to antifibrotic therapy regardless of specific ILD diagnosis.

Inhaled Treprostinil (INCREASE Trial): Approved in 2021 for pulmonary hypertension associated with ILD; a significant advance as the first approved therapy specifically for PH-ILD, demonstrating improvement in six-minute walk distance and reduction in clinical worsening.

Inhaled Treprostinil in IPF Itself (TETON Trials): The pooled TETON-1 and TETON-2 trials randomized 1,191 people with IPF. At 52 weeks the median change in lung capacity (FVC) was -45.4 ml on inhaled treprostinil against -161.7 ml on placebo; 41 people (6.9%) died against 56 (9.4%). Cough was the most common side effect.

Cryobiopsy: Transbronchial cryobiopsy is gaining acceptance as a less invasive alternative to surgical lung biopsy. Meta-analyses show comparable diagnostic yield with lower morbidity, though pneumothorax and bleeding rates require attention. The 2022 guideline conditionally regards transbronchial cryobiopsy as an acceptable alternative to surgical lung biopsy "in centers with appropriate expertise".

Genomic and Transcriptomic Profiling: Gene expression profiling of transbronchial biopsy samples (a less invasive procedure than surgery, though still a biopsy) can distinguish UIP from non-UIP patterns, potentially reducing need for surgical biopsy. One molecular classifier, validated in 49 patients, identified UIP with 88% specificity and 70% sensitivity. The 2022 guideline made no recommendation for or against genomic classifier testing.

Senescence and Epigenetic Targeting: Senolytic agents (navitoclax, dasatinib + quercetin) targeting senescent AEC II cells are in early-phase clinical trials for IPF. Epigenetic modifications (histone deacetylase inhibition) represent another emerging therapeutic strategy.

Artificial Intelligence in HRCT: Deep learning algorithms can identify UIP and NSIP patterns on HRCT with accuracy approaching expert thoracic radiologists, and can quantify fibrosis extent to track progression.

Glucagon-like peptide-1 Receptor Agonists in ILD: Preliminary data suggests metabolic comorbidities (obesity, diabetes) accelerate ILD progression; glucagon-like peptide-1 agonists may have anti-fibrotic properties beyond glycemic control.

Key Research Papers

  1. Raghu G, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. — doi:10.1164/rccm.202202-0399ST
  2. Travis WD, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748. — doi:10.1164/rccm.201308-1483ST
  3. Richeldi L, et al. (INPULSIS). Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071–2082. — doi:10.1056/NEJMoa1402584
  4. King TE, et al. (ASCEND). A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2083–2092. — doi:10.1056/NEJMoa1402582
  5. Flaherty KR, et al. (INBUILD). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. — doi:10.1056/NEJMoa1908681
  6. Distler O, et al. (SENSCIS). Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518–2528. — doi:10.1056/NEJMoa1903076
  7. Raghu G, et al. Diagnosis of Idiopathic Pulmonary Fibrosis: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. — doi:10.1164/rccm.201807-1255ST
  8. Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691. — doi:10.7326/0003-4819-156-10-201205150-00004
  9. Cottin V, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593. — doi:10.1183/09031936.05.00021005
  10. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis (PANTHER-IPF). N Engl J Med. 2012;366(21):1968–1977. — doi:10.1056/NEJMoa1113354
  11. Waxman A, et al. (INCREASE). Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384(4):325–334. — doi:10.1056/NEJMoa2008470
  12. Spagnolo P, Rossi G, Cavazza A, et al. Hypersensitivity Pneumonitis: A Comprehensive Review. J Investig Allergol Clin Immunol. 2015;25(4):237–250. — PubMed PMID: 26310038
  13. Seibold MA, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512. — doi:10.1056/NEJMoa1013660
  14. Collard HR, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265–275. — doi:10.1164/rccm.201604-0801CI
  15. Johannson KA, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Curr Respir Care Rep. 2013;2(4):233–240. — doi:10.1007/s13665-013-0065-x
  16. Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2). — PubMed PMID: 32646919
  17. Chua CG, Fan Z, Phua HP, et al. A comparison of clinical phenotype and outcomes in anti- melanoma differentiation-associated protein 5 dermatomyositis and anti-synthetase syndrome in a multiethnic cohort in Singapore. Front Med (Lausanne). 2026;13:1969582. — PubMed PMID: 42935629
  18. Raghu G, Flaherty KR, Lederer DJ, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7(6):487–496. — PubMed PMID: 30948346
  19. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193–2202. — PubMed PMID: 40387033
  20. Maher TM, Assassi S, Azuma A, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2203–2214. — PubMed PMID: 40388329
  21. Oldham JM, Assassi S, Azuma A, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. Eur Respir J. 2026. — PubMed PMID: 42532543
  22. Nathan SD, Smith P, Deng C, et al. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026. — PubMed PMID: 42776606
  23. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024;76(8):1182–1200. — PubMed PMID: 38978310
  24. Heinzerling A, Flattery J, Cummings KJ, et al. Silicosis among Workers Fabricating Engineered Stone ("Quartz") Countertops in California, 2019-2026. NEJM Evid. 2026;5(9):EVIDpha2600187. — PubMed PMID: 42584953
  25. Fazio JC, Gandhi SA, Flattery J, et al. Silicosis Among Immigrant Engineered Stone (Quartz) Countertop Fabrication Workers in California. JAMA Intern Med. 2023;183(9):991–998. — PubMed PMID: 37486642

PubMed Topic Searches

The following PubMed topic searches surface the current peer-reviewed literature on Interstitial Lung Disease. Each link opens a live PubMed query; results update as new papers are indexed.

  1. PubMed: Search: interstitial lung disease
  2. PubMed: Search: idiopathic pulmonary fibrosis
  3. PubMed: Search: pirfenidone pulmonary fibrosis
  4. PubMed: Search: nintedanib pulmonary fibrosis
  5. PubMed: Search: hypersensitivity pneumonitis
  6. PubMed: Search: nonspecific interstitial pneumonia
  7. PubMed: Search: cryptogenic organizing pneumonia
  8. PubMed: Search: connective tissue disease interstitial lung
  9. PubMed: Search: ILD high resolution CT
  10. PubMed: Search: lung transplantation pulmonary fibrosis
  11. PubMed: Search: progressive pulmonary fibrosis
  12. PubMed: Search: ILD bronchoalveolar lavage

Back to Table of Contents

Connections

Back to Table of Contents